Search

Your search keyword '"Weaver, Fred"' showing total 1,189 results
Start Over Author "Weaver, Fred"
1,189 results on '"Weaver, Fred"'

353. The contemporary management of renal artery aneurysms

Author

Klausner, Jill Q., primary, Lawrence, Peter F., additional, Harlander-Locke, Michael P., additional, Coleman, Dawn M., additional, Stanley, James C., additional, Fujimura, Naoki, additional, Itoga, Nathan K., additional, Mell, Matthew W., additional, Duncan, Audra A., additional, Oderich, Gustavo S., additional, Rizvi, Adnan Z., additional, Inui, Tazo, additional, Hye, Robert J., additional, Pak, Peter, additional, Lee, Christopher, additional, Cayne, Neal S., additional, Loeffler, Jacob, additional, Humphries, Misty D., additional, Abularrage, Christopher, additional, Bove, Paul G., additional, Feezor, Robert J., additional, Azarbal, Amir F., additional, Smeds, Matthew R., additional, Ladowski, Joseph M., additional, Ladowski, Joseph S., additional, Leung, Vivian M., additional, Hsiang, York N., additional, Dominguez, Josefina, additional, Weaver, Fred A., additional, and Morasch, Mark D., additional

Published
2015
Full Text
View/download PDF

357. Clinical use of topical thrombin as a surgical hemostat

Author

Weaver, Fred

Subjects
Targets and Therapy [Biologics]
Abstract

Wesley K Lew1, Fred A Weaver21University of Southern California, Department of Surgery, Los Angeles, CA, USA; 2CardioVascular Thoracic Institute at the University of Southern California, Los Angeles, CA, USAAbstract: When surgical ligation of bleeding fails, or is not possible, surgeons rely on a number of hemostatic aids, including thrombin. This review discusses the history, pharmacology and clinical application of thrombin as a surgical hemostat. The initial thrombin was bovine in origin, but its use has been complicated by the formation of antibodies that cross react with human coagulation factors. This has been associated with life threatening bleeding and in some circumstances anaphylaxis and death. Human thrombin, isolated from pooled plasma of donors, has been developed in an effort to minimize these risks, but its downside is the potential of transmitting blood-borne pathogens and limited availability. Recently a recombinant thrombin has been developed and approved for use by the FDA. It has the advantage of being minimally antigenic and devoid of the risk if viral transmission. Thrombin is often used in conjunction with other hemostatic aids, including absorbable agents (like gelfoam, collagen, and cellulose), and with fibrinogen in fibrin glues. The last part of this review will discuss these agents in detail, and review their clinical applications.Keywords: bovine, recombinant, human, thrombin, antigenicity, antibodies

Published
2008

360. Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long‐term outcomes.

Author

Zile, Michael R., Lindenfeld, JoAnn, Weaver, Fred A., Zannad, Faiez, Galle, Elizabeth, Rogers, Tyson, and Abraham, William T.

Subjects
*CARDIAC pacing, *VENTRICULAR ejection fraction, *BRAIN natriuretic factor, *HEART failure patients, *BAROREFLEXES, *HEART assist devices, *AEROBIC capacity
Abstract

Aims: Carotid baroreflex activation therapy (BAT) restores baroreflex sensitivity and modulates the imbalance in cardiac autonomic function in patients with heart failure with reduced ejection fraction (HFrEF). We tested the hypothesis that treatment with BAT significantly reduces cardiovascular mortality and heart failure morbidity and provides long‐term safety and sustainable symptomatic improvement. Methods and results: BeAT‐HF was a prospective, multicentre, randomized, two‐arm, parallel‐group, open‐label, non‐implanted control trial. New York Heart Association (NYHA) class III subjects, ejection fraction ≤35%, previous heart failure hospitalization or N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) >400 pg/ml, no class I indication for cardiac resynchronization therapy and NT‐proBNP <1600 pg/ml were randomized to BAT plus optimal medical management (BAT group) or optimal medical management alone (control). The primary endpoint was cardiovascular mortality and HF morbidity; additional pre‐specified endpoints included durability of safety, quality of life (QOL), exercise capacity (6‐min hall walk distance [6MHWD]), functional status (NYHA class), hierarchical composite win ratio, freedom from all‐cause death, left ventricular assists device (LVAD) implantation, heart transplant. Overall, 323 patients had 332 primary events, median follow‐up was 3.6 years/patient. Both primary endpoint (rate ratio 0.94, 95% confidence interval [CI] 0.57–1.57; p = 0.82) and components of the primary endpoints were not significantly different between BAT and control. The system‐ and procedure‐related major adverse neurological and cardiovascular event‐free rate remained 97% throughout the trial. Symptom improvement (QOL, 6MHWD, NYHA class, all nominal p < 0.001) in the BAT group was durable in time, sustainable in extent. Win ratio (1.26, 95% CI 1.02–1.58) and freedom from all‐cause death, LVAD implantation, heart transplant (hazard ratio 0.66, 95% CI 0.43–1.01) favoured the BAT group but did not reach statistical significance. Conclusion: The BeAT‐HF primary endpoint was neutral; however, BAT provided safe, effective, and sustainable improvements in HFrEF patient's functional status, 6MHWD and QOL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

363. Association of left subclavian artery coverage without revascularization and spinal cord ischemia in patients undergoing thoracic endovascular aortic repair: A Vascular Quality Initiative® analysis.

Author

Teixeira, Pedro G. R., Woo, Karen, Beck, Adam W., Scali, Salvatore T., Weaver, Fred A., Teixeira, Pedro Gr, and Society for Vascular Surgery, Vascular Quality Initiative (VQI)®

Subjects
ISCHEMIA diagnosis, ISCHEMIA prevention, SUBCLAVIAN artery surgery, AORTIC diseases, BLOOD vessel prosthesis, CHI-squared test, CLINICAL medicine, DATABASES, ISCHEMIA, MULTIVARIATE analysis, SUBCLAVIAN artery, TIME, LOGISTIC regression analysis, KEY performance indicators (Management), TREATMENT effectiveness, RETROSPECTIVE studies, HOSPITAL mortality, ODDS ratio, THORACIC aorta, EQUIPMENT & supplies, SURGERY
Abstract

Objectives Investigate the impact of left subclavian artery coverage without revascularization on spinal cord ischemia development in patients undergoing thoracic endovascular aortic repair. Methods The Vascular Quality Initiative thoracic endovascular aortic repair module (April 2011-July 2014) was analyzed. Patients undergoing left subclavian artery coverage were divided into two groups according to revascularization status. The association between left subclavian artery revascularization with the primary outcome of spinal cord ischemia and the secondary outcome of stroke was assessed with multivariable analysis adjusting for between-group baseline differences. Results The left subclavian artery was covered in 508 (24.6%) of the 2063 thoracic endovascular aortic repairs performed. Among patients with left subclavian artery coverage, 58.9% underwent revascularization. Spinal cord ischemia incidence was 12.1% in the group without revascularization compared to 8.5% in the group undergoing left subclavian artery revascularization (odds ratio (95%CI): 1.48(0.82-2.68), P = 0.189). Multivariable analysis adjustment identified an independent association between left subclavian artery coverage without revascularization and the incidence of spinal cord ischemia (adjusted odds ratio (95%CI): 2.29(1.03-5.14), P = 0.043). Although the incidence of stroke was also higher for the group with a covered and nonrevascularized left subclavian artery (12.1% versus 8.5%), this difference was not statistically significant after multivariable analysis (adjusted odds ratio (95%CI): 1.55(0.74-3.26), P = 0.244). Conclusion For patients undergoing left subclavian artery coverage during thoracic endovascular aortic repair, the addition of a revascularization procedure was associated with a significantly lower incidence of spinal cord ischemia. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

365. Selection criterion for endovascular aortic repair in those with chronic kidney disease.

Author

Khoury, Mitri K., Thornton, Micah A., Weaver, Fred A., Ramanan, Bala, Tsai, Shirling, Timaran, Carlos H., and Modrall, J. Gregory

Abstract

Endovascular aortic repair (EVAR) is the preferred method of repair for abdominal aortic aneurysms (AAAs). However, patients with advanced chronic kidney disease (CKD) are a high-risk group, and it is unknown which patients with CKD benefit from EVAR vs continued surveillance. The purpose of this study was to identify which patients with advanced CKD may benefit from EVAR. The Vascular Quality Initiative Database was utilized to identify elective EVARs for AAAs. Patients were excluded if they underwent urgent or emergent repairs. CKD stages were categorized based on preoperative estimated glomular filtration rate (eGFR) and dialysis status. Predicted 1-year mortality of untreated AAAs was calculated by modifying a validated comorbidity score that predicts 1-year mortality (Gagne Index) without repair. The primary outcome was actual 1-year mortality, which was compared with the predicted 1-year mortality without repair. A total of 34,926 patient met study criteria. There were differences in Gagne Indices among the varying classes of CKD. Patients with CKD 4 and CKD 5 had the highest 1-year mortality rates, followed by CKD 3b, which was significantly higher than those with CKD 1 and CKD 2. Patients with CKD 4 had no differences between actual 1-year mortality with EVAR and predicted 1-year survival without EVAR across all AAA sizes. Those with CKD 5 had worse actual 1-year survival with EVAR than predicted 1-year survival without EVAR for AAAs <5.5 cm. Patients with CKD 5 only experienced an actual mortality benefit with EVAR compared with predicted 1-year mortality without EVAR for AAAs ≥7.0 cm. The current data suggest that patients with CKD 3b, 4, and 5 represent a high-risk group who may not benefit from elective EVAR utilizing traditional size criteria. Patients with CKD 4 and 5 with AAAs <5.5 cm do not benefit from elective EVAR. In patients with CKD 5, elective EVAR may need to be reserved for AAAs ≥7.0 cm unless there are other concerning anatomic characteristics. [Display omitted] [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

380. Thrombin use in surgery: an evidence-based review of its clinical use

Author

Ham,Sung W, Lew,Wesley K, Weaver,Fred A, Ham,Sung W, Lew,Wesley K, and Weaver,Fred A

Abstract

This paper has been retracted.Sung W Ham1, Wesley K Lew1, Fred A Weaver21University of Southern California, Department of Surgery, Los Angeles, CA, 2Cardiovascular Thoracic Institute at the University of Southern California, Los Angeles, USAAbstract: When surgical ligation of bleeding fails, or is not possible, surgeons rely on a ­number of hemostatic aids, including thrombin. This review discusses the history, pharmacology and clinical application of thrombin as a surgical hemostat. The initial thrombin was bovine in origin, but its use has been complicated by the formation of antibodies that cross-react with human coagulation factors. This has been associated with life-threatening bleeding and in some circumstances anaphylaxis and death. Human thrombin, isolated from pooled plasma of donors, was developed in an effort to minimize these risks, but its downsides are its limited availability and the potential for transmitting blood-borne pathogens. Recently a recombinant thrombin has been developed, and approved for use by the FDA. It has the advantage of being minimally antigenic and devoid of the risk of viral transmission. Thrombin is often used in conjunction with other hemostatic aids, including absorbable agents such as Gelfoam, and with fibrinogen in fibrin glues. The last part of this review will discuss these agents in detail, and review their clinical applications.Keywords: bovine, recombinant, human, thrombin, antigenicity, antibodies, food drug ­administration (FDA)

Published
2010

381. Clinical use of topical thrombin as a surgical hemostat

Author

Lew,Wesley K, Weaver,Fred A, Lew,Wesley K, and Weaver,Fred A

Abstract

Wesley K Lew1, Fred A Weaver21University of Southern California, Department of Surgery, Los Angeles, CA, USA; 2CardioVascular Thoracic Institute at the University of Southern California, Los Angeles, CA, USAAbstract: When surgical ligation of bleeding fails, or is not possible, surgeons rely on a number of hemostatic aids, including thrombin. This review discusses the history, pharmacology and clinical application of thrombin as a surgical hemostat. The initial thrombin was bovine in origin, but its use has been complicated by the formation of antibodies that cross react with human coagulation factors. This has been associated with life threatening bleeding and in some circumstances anaphylaxis and death. Human thrombin, isolated from pooled plasma of donors, has been developed in an effort to minimize these risks, but its downside is the potential of transmitting blood-borne pathogens and limited availability. Recently a recombinant thrombin has been developed and approved for use by the FDA. It has the advantage of being minimally antigenic and devoid of the risk if viral transmission. Thrombin is often used in conjunction with other hemostatic aids, including absorbable agents (like gelfoam, collagen, and cellulose), and with fibrinogen in fibrin glues. The last part of this review will discuss these agents in detail, and review their clinical applications.Keywords: bovine, recombinant, human, thrombin, antigenicity, antibodies

Published
2008

382. Colaboradores

Author

Abou-Zamzam, Ahmed M., Jr., Abularrage, Christopher J., AbuRahma, Ali F., Acher, Charles W., Acosta, Stefan, Airhart, Nathan, Akar, Ahmet Rüçhan, Alef, Matthew J., Alimi, Yves S., Alomari, Ahmad, Arcelus, Juan I., Arko, Frank R., III, Armstrong, David G., Arnold, Maggie, Arthurs, Zachary M., Atkins, Marvin D., Atnip, Robert, Aziz, Faisal, Azizzadeh, Ali, Back, Martin R., Baig, M. Shadman, Ballard, Jeffrey L., Bartholomew, John R., Baumeister, Ruediger G.H., Beattie, William Scott, Bechara, Carlos F., Beck, Adam W., Beckman, Joshua A., Belkin, Michael, Ben-Haim, Simona, Bennett, Kyla M., Berceli, Scott A., Bernas, Michael J., Berookhim, Boback M., Bianchi, Christian, Björck, Martin, Black, James H., III, Blankensteijn, Jan D., Bower, Thomas C., Brummel-Ziedins, Kathleen E., Bush, Ruth L., Byrne, John, Caliste, Xzabia A., Calligaro, Keith D., Cambria, Richard P., Cao, Piergiorgio, Caprini, Joseph A., Carlson, Gregory D., Carman, Teresa L., Carpenter, Jeffrey P., Casale, George P., Cayne, Neal S., Chaer, Rabih A., Chaikof, Elliot L., Cheng, Stephen W.K., Cheville, Andrea L., Chin, Jason, Chung, Jayer, Clair, Daniel G., Clark, Sara, Clouse, W. Darrin, Comerota, Anthony J., Conrad, Mark F., Cooper, Christopher J., Cooper, Leslie T., Jr., Corriere, Matthew A., Cull, David L., Curci, John A., Dalsing, Michael C., Damrauer, Scott M., De Rango, Paola, Deaton, David H., Demetriades, Demetrios, Desai, Sapan S., DiMuzio, Paul J., Dosluoglu, Hasan H., Dougherty, Matthew J., Duncan, Audra A., Durdu, Serkan, Eagleton, Matthew J., Earnshaw, Jonothan J., Eberhardt, Robert T., Edwards, Matthew S., Eidt, John F., Eliason, Jonathan L., Endean, Eric D., Eskandari, Mark K., Fairman, Ronald M., Farber, Alik, Faries, Peter L., Fillinger, Mark, Fishman, Steven J., Forbes, Thomas L., Fox, Charles J., Freischlag, Julie A., Gamble, Gail L., Geary, Randolph L., Gillespie, David L., Glebova, Natalia O., Gloviczki, Peter, Goodney, Philip P., Gopal, Kapil, Gornik, Heather L., Gottsäter, Anders, Greenberg, Roy K., Greene, Arin K., Guevara, Carlos J., Guzman, Raul J., Hamdan, Allen, Hansen, Kimberley J., Harris, Linda M., Hartung, Olivier, Hass, Stephen M., Henke, Peter K., Herrick, Ariane L., Holt, Peter J.E., Huber, Thomas S., Hurie, Justin B., Iafrati, Mark D., Inaba, Kenji, Islam, Arsalla, Israel, Ora, Jacobowitz, Glenn, Jaffer, Iqbal H., Jiang, Zhihua, Jordan, William, Kabnick, Lowell S., Kakisis, John, Kalapatapu, Venkat R., Kalish, Jeffrey, Kalra, Manju, Kang, Jeanwan, Kashyap, Vikram S., Kauffman, Paulo, Kauvar, David S., Killewich, Lois A., Kim, Esther S.H., Kirkwood, Melissa L., Knepper, Jordan P., Kohler, Ted R., Kool, Leo J. Schultze, Kraiss, Larry W., Kumar, Hari R., Kwolek, Christopher J., Labropoulos, Nicos, Lakin, Ryan O., Lal, Brajesh K., Lamb, Kathleen M., LaMuraglia, Glenn M., Landesberg, Giora, Lawson, Jeffrey H., Lee, Jason T., León, Luis R., Jr., Lew, Wesley K., Liapis, Christos, Liebman, Howard A., Lilly, Michael P., Lin, Peter H., Lindblad, Bengt, Lipsett, Pamela A., Litt, Harold, Lo, Ruby C., Long, William B., Lum, Ying Wei, Lurie, Fedor, Lyden, Sean P., Makaroun, Michel S., Maldonado, Thomas S., Maley, Bruce E., Mann, Kenneth G., Markose, George, Marston, William A., Martin, Matthew J., Martin, Michelle C., Mastracci, Tara M., Matsumura, Jon S., Maxfield, Kathleen O'Malley, McKinsey, James F., McLafferty, Robert B., Mehta, Manish, Meier, George H., Menard, Matthew T., Messina, Louis M., Mills, Joseph L., Sr., Milner, Ross, Minc, Samantha, Modrall, J. Gregory, Mohler, Emile R., III, Morasch, Mark D., Muir, Lindsay, Mulhall, John P., Mulliken, John B., Myers, Daniel J., Myers, Stuart I., Naylor, A. Ross, Nayor, Matthew G., Neglén, Peter, Neville, Richard F., Nguyen, Louis L., Nouvong, Aksone, O'Donnell, Thomas F., Jr., Oderich, Gustavo S., Oldenburg, W. Andrew, Olin, Jeffrey W., Orringer, Carl, Ouma, Geoffrey O., Owens, Christopher D., Ozaki, C. Keith, Paolini, David, Papia, Giuseppe, Pascarella, Luigi, Passman, Marc A., Patel, Virendra I., Paty, Philip, Pearce, Benjamin, Perler, Bruce A., Pipinos, Iraklis I., Pounds, Lori L., Powell, Richard J., Puggioni, Alessandra, Qu, Zheng, Raffetto, Joseph D., Raju, Seshadri, Rasmussen, Todd E., Rathbun, Suman, Ravin, Reid A., Reid, Donald B., Rialon, Kristy L., Ricotta, John J., Ricotta, Joseph J., Rizvi, Addi Z., Rockman, Caron B., Rockson, Stanley G., Roddy, Sean P., Rogers, Carolyn R., Rowe, Vincent L., Rzucidlo, Eva M., Sadek, Mikel, Safi, Hazim J., Sambol, Elliot B., Schanzer, Andres, Schermerhorn, Marc L., Schneider, Joseph R., Schneider, Peter A., Shalhub, Sharene, Shortell, Cynthia, Shuja, Fahad, Sidawy, Anton N., Simons, Jessica P., Singh, Michael J., Singh, Niten N., Slater, Leigh Ann, Smith, Ann DeBord, Stanley, James C., Starnes, Benjamin W., Sternbergh, W. Charles, III, Stone, David H., Stone, Patrick A., Sullivan, Timothy M., Sumner, David S., Sumpio, Bauer, Tefera, Girma, Thompson, Matt M., Timaran, Carlos H., Titus, Jessica M., Trenor, Cameron C., III, Turney, Eric J., Upchurch, Gilbert R., Jr., Valentine, R. James, Velazquez, Omaida, Velazquez-Ramirez, Gabriela, Wakefield, Thomas W., Walsh, Daniel B., Wang, Bo, Wang, Grace J., Warrington, Kenneth J., Weaver, Fred A., Weitz, Ilene Ceil, Weitz, Jeffrey I., Witte, Marlys H., Wolosker, Nelson, Woo, Edward Y., Woo, Karen, Wyers, Mark C., Wynn, Mimi, Zhou, Wei, and Zierler, R. Eugene

Published
2016
Full Text
View/download PDF

383. Contributors

Author

Baker, Aaron C., Blackbourne, Lorne H., Boffard, Kenneth, Borraez, Oswaldo, Bowyer, Mark W., Brohi, Karim, Butler, Frank K., Cannon, Jeremy W., Civil, Ian D., Clasper, Jon, Cleanthis, Marcus, Clouse, W. Darrin, Davidovic, Lazar B., Dawson, David L., Demetriades, Demetrios, DuBose, Joseph J., Fabian, Timothy C., Feliciano, David V., Fox, Charles J., Gillespie, David L., Herscu, Gabriel, Hettiaratchy, Shehan, Hodgetts, Timothy, Hoffman, Aaron, Holcomb, John B., Inaba, Kenji, Jenkins, Donald H., Jenkins, Michael, Karram, Tony, Knipp, Brian S., Kumar, Neil G., Leppäniemi, Ari K., Lovrić, Zvonimir, Midwinter, Mark, Moreno, Luis A., Morrison, Jonathan J., Murilo, Rossi, Nitecki, Samy, Nott, David M., Patel, Chirag M., Pavić, Predrag, Peck, Michael A., Porta, Rina, Pronchenko, Alexander A., Quan, Reagan W., Ranatunga, Dinesh G., Rasmussen, Todd E., Ratnayake, Amila S., Renfrew, Ian, Reva, Viktor A., Rich, Norman M., Samarasinghe, Bandula, Samokhvalov, Igor M., Savage, Stephanie A., Savolainen, Hannu, Scott, Daniel J., Shalhub, Sherene, Sheriffdeen, Abdul H., Singh, Niten, Sise, Michael J., Starnes, Benjamin, Tai, Nigel R.M., Talving, Peep, Ulloa, Jorge H., Villamaria, Carole Y., Walker, Alasdair J., Weaver, Fred A., and Wijeyaratne, Mandika

Published
2016
Full Text
View/download PDF

386. ACCF/ACR/AIUM/ASE/IAC/SCAI/SCVS/SIR/SVM/SVS/SVU 2013 Appropriate Use Criteria for Peripheral Vascular Ultrasound and Physiological Testing Part II: Testing for Venous Disease and Evaluation of Hemodialysis Access

Author

Gornik, Heather L., primary, Gerhard-Herman, Marie D., additional, Misra, Sanjay, additional, Mohler, Emile R., additional, Zierler, R. Eugene, additional, Fazel, Reza, additional, Findeiss, Laura, additional, Fuchs, Richard, additional, Gillespie, John, additional, Gocke, John, additional, Heggeness, Michael H., additional, Hughes, Joseph P., additional, Lilly, Michael P., additional, Moore, Colleen, additional, Pellerito, John S., additional, Robbin, Michelle L., additional, Rooke, Thom W., additional, Rosenblatt, Melvin, additional, Weaver, Fred A., additional, White, Christopher J., additional, Wolk, Michael J., additional, Bailey, Steven R., additional, Doherty, John U., additional, Douglas, Pamela S., additional, Haidari, Z. Jenissa, additional, Hendel, Robert C., additional, Kramer, Christopher M., additional, Min, James K., additional, Patel, Manesh R., additional, Shaw, Leslee, additional, Stainback, Raymond F., additional, and Allen, Joseph M., additional

Published
2013
Full Text
View/download PDF

392. A Prospective Study of Carbon Dioxide Digital Subtraction versus Standard Contrast Arteriography in the Detection of Endoleaks in Endovascular Abdominal Aortic Aneurysm Repairs

Author

Huang, S. Grace, primary, Woo, Karen, additional, Moos, John M., additional, Han, Sukgu, additional, Lew, Wesley K., additional, Chao, Alex, additional, Hamilton, Ann, additional, Ochoa, Christian, additional, Hood, Douglas B., additional, Rowe, Vincent L., additional, and Weaver, Fred A., additional

Published
2013
Full Text
View/download PDF

394. Costs and Cost-Effectiveness of Carotid Stenting Versus Endarterectomy for Patients at Standard Surgical Risk

Author

Vilain, Katherine R., primary, Magnuson, Elizabeth A., additional, Li, Haiyan, additional, Clark, Wayne M., additional, Begg, Richard J., additional, Sam, Albert D., additional, Sternbergh, W. Charles, additional, Weaver, Fred A., additional, Gray, William A., additional, Voeks, Jenifer H., additional, Brott, Thomas G., additional, and Cohen, David J., additional

Published
2012
Full Text
View/download PDF

395. Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial

Author

Lal, Brajesh K, primary, Beach, Kirk W, additional, Roubin, Gary S, additional, Lutsep, Helmi L, additional, Moore, Wesley S, additional, Malas, Mahmoud B, additional, Chiu, David, additional, Gonzales, Nicole R, additional, Burke, J Lee, additional, Rinaldi, Michael, additional, Elmore, James R, additional, Weaver, Fred A, additional, Narins, Craig R, additional, Foster, Malcolm, additional, Hodgson, Kim J, additional, Shepard, Alexander D, additional, Meschia, James F, additional, Bergelin, Robert O, additional, Voeks, Jenifer H, additional, Howard, George, additional, and Brott, Thomas G, additional

Published
2012
Full Text
View/download PDF

400. Abstract 3: Restenosis following Carotid Artery Stenting and Endarterectomy in the Carotid Revascularization Endarterectomy versus Stenting Trial

Author

Lal, Brajesh K, primary, Beach, Kirk W, additional, Roubin, Gary S, additional, Lutsep, Helmi L, additional, Moore, Wesley S, additional, Malas, Mahmoud B, additional, Chiu, David, additional, Gonzales, Nicole R, additional, Burke, James L, additional, Rinaldi, Michael, additional, Elmore, James R, additional, Weaver, Fred A, additional, Narins, Craig R, additional, Foster, Malcolm, additional, Hodgson, Kim, additional, Shepard, Alexander D, additional, Meschia, James F, additional, Bergelin, Robert O, additional, Voeks, Jenifer H, additional, Howard, George, additional, and Brott, Thomas G, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results